| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8fa73639d3e2c89ec8e445daf969b7ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7641467e74b2b5e8fb2f4c28507f235 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate |
1999-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2006-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19042afcccafabfdf57b06cc3ee6cbfe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c04205c192adeaf74ac1f40cf02dd5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f63997fd4a751aea78cbc36fa6b524a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81820a64d6a5dfb466a835942fbc1943
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b72061b4961f2af0728b93214ea3aaf7 |
| publicationDate |
2006-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1105419-B1 |
| titleOfInvention |
Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
| abstract |
The present invention is directed toward peptide analogs of human myelin basic protein. The peptide analog is at least seven amino acids long and derived from residues 83 to 99 of human myelin basic protein. The analogs are altered from the native sequence at least at positions 91, 95, or 97. Additional alterations may be made at other positions. Pharmaceutical compositions containing these peptide analogs are provided. The peptide analogs are useful for treating multiple sclerosis. |
| priorityDate |
1998-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |